Covenant Partners’s Eli Lilly LLY Stock Holding History

Covenant Partners’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-495	Closed	-$532K	–	74
2025 Q4	$532K	Hold	495	–	–	0.16%	66
2025 Q3	$378K	Sell	495 -1	-0.2%	-$744	0.11%	90
2025 Q2	$387K	Hold	496	–	–	0.12%	90
2025 Q1	$410K	Hold	496	–	–	0.13%	80
2024 Q4	$383K	Sell	496 -4,875	-91%	-$4.04M	0.12%	92
2024 Q3	$4.76M	Buy	5,371 +4,370	+437%	+$3.93M	1.38%	12
2024 Q2	$906K	Hold	1,001	–	–	0.28%	49
2024 Q1	$779K	Sell	1,001 -2	-0.2%	-$1.42K	0.23%	60
2023 Q4	$585K	Hold	1,003	–	–	0.18%	83
2023 Q3	$539K	Buy	1,003 +505	+101%	+$260K	0.2%	88
2023 Q2	$234K	Buy	+498	New	+$209K	0.08%	164

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Covenant Partners's LLY Position: Q1 2026 in Review

Covenant Partners sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 495 shares — an estimated $532K sold.

Covenant Partners first reported a position in LLY in Q2 2023 and held it in 11 quarters. The position peaked at $4.76M in Q3 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Covenant Partners reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
Covenant Partners sold 495 Eli Lilly shares in Q1 2026, an estimated $532K.
Covenant Partners first reported a position in Eli Lilly in Q2 2023 and held it in 11 quarters.
Covenant Partners's Eli Lilly position peaked at $4.76M in Q3 2024.
4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Covenant Partners's 13F filing for Q1 2026.